How platinib works

Pralsetinib (Pralsetinib) is an oral, small-molecule inhibitor of the tyrosine kinase receptor encoded by the proto-oncogene RET (rearranged during transfection), which is mutated or altered in several cancers, including 1% to 2% of non-small cell lung cancer (NSCLC) and approximately 10% of other thyroid cancers. Platinib was found to be a potent inhibitor of cell growth and proliferation in tumor cell lines and experimental tumor models harboring RET mutations or RET gene fusions. In open-label trials of platinib in patients with advanced or metastatic NSCLC with RET alterations, objective response rates ranged from 56% to 85%.